CRISPR Therapeutics AG (CRSP) stock price moved 6.25% away from 20-Days Simple Moving Average, -11.50% from 50-Days Simple Moving Average and separated -24.76% from 200 Days Simple Moving Average. CRISPR Therapeutics AG (CRSP) reported loss -2.96% in recent buying and selling session with closing price of $ 37.70. The stock’s traded 0.95 million shares in session while it holds an average volume of 0.96 million shares. The CRSP switched 128.35% away from its 52 week minimum and distanced -48.99% from its 52 week peak. The volatility change in the previous week has observed by 6.97% and experienced of 8.23% change in the last month.
The short ratio in the company’s stock is documented at 4.00 and the short float is around of 11.91%. The Company kept a record of 32.22 million floated shares and 49.71 million shares outstanding. The average true range of the stock is observed at 2.73 and the relative strength index of the stock is recorded at 49.28.
Analyst notified mean rating at 2.40 after consensus analysis. (Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Keep in mind that Investors should not rely only on an analyst’s recommendation when taking a decision whether to buy, hold, or sell a stock. Instead, they should also do their own research—such as reading the prospectus for new companies or for public companies, the quarterly and annual reports filed with the SEC—to confirm whether a particular investment is appropriate for them in light of their individual financial circumstances.
CRISPR Therapeutics AG (CRSP) Stock Profitability Levels:
The company made Return on equity of -39.60% in last 12 months period. Return on assets ratio of the Company was -28.50%. Its return on investment ratio was -32.00% in the trailing 12 months period.
Analyst established EPS growth expected to grow of 18.10% for this year and EPS growth for next year is likely to attain at -8.90%.
Looking about the past performance history, the company plunged 5.93% for the last five trades and expanded 2.89% in one month period. The stock deteriorated -19.97% during the past three month period and discounted -28.50% in half year. During the yearly overview it upgraded 110.14% and shown 60.56% year to date performance.